ArticleJournal of Cancer2019

Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial.

Seung Tae Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.